CardioWest temporary total artificial heart.

Anthony Platis, Douglas F Larson

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: The CardioWest temporary total artificial heart (TAH-t) replaces both native ventricles of the heart and is more beneficial for a select group of patients than most other typical ventricular assist devices (VADs). This review will expand on the current literature and highlight the chronology of this device. The CardioWest TAH-t has been implanted in over 715 patients at 30 multiple institutional centers worldwide as a bridge-to-transplant (BTT) since 1993. The mechanical flow dynamics of the device are manufactured and designed differently from other traditional VADs, allowing increased outputs and normal filling pressures, allowing for sufficient organ and tissue perfusion and dramatic recoveries, allowing patients to return to an almost normal quality of life. RESULTS: There was a 79% survival to transplant achievement in the protocol group who received the TAH-t versus a 46% in the control group (P < 0.001). Furthermore, there was a 70% survival rate at one year in the protocol group versus 31% in the control group (P < 0.001). The one- and five-year survival rates after transplantation were 69% and 34%, respectively, in the control group and 86% and 64%, respectively, in the protocol group. CONCLUSION: It is evident that the advancement of modern engineering and medicine has made way for a reliable and durable device that provides a promising future in the field of end-stage heart failure.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalPerfusion
Volume24
Issue number5
StatePublished - Sep 2009

Fingerprint

Artificial heart
Artificial Heart
Transplants
Heart-Assist Devices
Equipment and Supplies
Control Groups
Survival Rate
Chronology
Modern 1601-history
Group
Medicine
Heart Ventricles
Heart Failure
Perfusion
Transplantation
Quality of Life
Tissue
Pressure
Recovery
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Advanced and Specialized Nursing
  • Safety Research

Cite this

CardioWest temporary total artificial heart. / Platis, Anthony; Larson, Douglas F.

In: Perfusion, Vol. 24, No. 5, 09.2009, p. 341-346.

Research output: Contribution to journalArticle

Platis, A & Larson, DF 2009, 'CardioWest temporary total artificial heart.', Perfusion, vol. 24, no. 5, pp. 341-346.
Platis, Anthony ; Larson, Douglas F. / CardioWest temporary total artificial heart. In: Perfusion. 2009 ; Vol. 24, No. 5. pp. 341-346.
@article{a3c83898d5e04a72a7cd25f1cdaab78f,
title = "CardioWest temporary total artificial heart.",
abstract = "BACKGROUND: The CardioWest temporary total artificial heart (TAH-t) replaces both native ventricles of the heart and is more beneficial for a select group of patients than most other typical ventricular assist devices (VADs). This review will expand on the current literature and highlight the chronology of this device. The CardioWest TAH-t has been implanted in over 715 patients at 30 multiple institutional centers worldwide as a bridge-to-transplant (BTT) since 1993. The mechanical flow dynamics of the device are manufactured and designed differently from other traditional VADs, allowing increased outputs and normal filling pressures, allowing for sufficient organ and tissue perfusion and dramatic recoveries, allowing patients to return to an almost normal quality of life. RESULTS: There was a 79{\%} survival to transplant achievement in the protocol group who received the TAH-t versus a 46{\%} in the control group (P < 0.001). Furthermore, there was a 70{\%} survival rate at one year in the protocol group versus 31{\%} in the control group (P < 0.001). The one- and five-year survival rates after transplantation were 69{\%} and 34{\%}, respectively, in the control group and 86{\%} and 64{\%}, respectively, in the protocol group. CONCLUSION: It is evident that the advancement of modern engineering and medicine has made way for a reliable and durable device that provides a promising future in the field of end-stage heart failure.",
author = "Anthony Platis and Larson, {Douglas F}",
year = "2009",
month = "9",
language = "English (US)",
volume = "24",
pages = "341--346",
journal = "Perfusion",
issn = "0267-6591",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - CardioWest temporary total artificial heart.

AU - Platis, Anthony

AU - Larson, Douglas F

PY - 2009/9

Y1 - 2009/9

N2 - BACKGROUND: The CardioWest temporary total artificial heart (TAH-t) replaces both native ventricles of the heart and is more beneficial for a select group of patients than most other typical ventricular assist devices (VADs). This review will expand on the current literature and highlight the chronology of this device. The CardioWest TAH-t has been implanted in over 715 patients at 30 multiple institutional centers worldwide as a bridge-to-transplant (BTT) since 1993. The mechanical flow dynamics of the device are manufactured and designed differently from other traditional VADs, allowing increased outputs and normal filling pressures, allowing for sufficient organ and tissue perfusion and dramatic recoveries, allowing patients to return to an almost normal quality of life. RESULTS: There was a 79% survival to transplant achievement in the protocol group who received the TAH-t versus a 46% in the control group (P < 0.001). Furthermore, there was a 70% survival rate at one year in the protocol group versus 31% in the control group (P < 0.001). The one- and five-year survival rates after transplantation were 69% and 34%, respectively, in the control group and 86% and 64%, respectively, in the protocol group. CONCLUSION: It is evident that the advancement of modern engineering and medicine has made way for a reliable and durable device that provides a promising future in the field of end-stage heart failure.

AB - BACKGROUND: The CardioWest temporary total artificial heart (TAH-t) replaces both native ventricles of the heart and is more beneficial for a select group of patients than most other typical ventricular assist devices (VADs). This review will expand on the current literature and highlight the chronology of this device. The CardioWest TAH-t has been implanted in over 715 patients at 30 multiple institutional centers worldwide as a bridge-to-transplant (BTT) since 1993. The mechanical flow dynamics of the device are manufactured and designed differently from other traditional VADs, allowing increased outputs and normal filling pressures, allowing for sufficient organ and tissue perfusion and dramatic recoveries, allowing patients to return to an almost normal quality of life. RESULTS: There was a 79% survival to transplant achievement in the protocol group who received the TAH-t versus a 46% in the control group (P < 0.001). Furthermore, there was a 70% survival rate at one year in the protocol group versus 31% in the control group (P < 0.001). The one- and five-year survival rates after transplantation were 69% and 34%, respectively, in the control group and 86% and 64%, respectively, in the protocol group. CONCLUSION: It is evident that the advancement of modern engineering and medicine has made way for a reliable and durable device that provides a promising future in the field of end-stage heart failure.

UR - http://www.scopus.com/inward/record.url?scp=77950351528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950351528&partnerID=8YFLogxK

M3 - Article

C2 - 19917572

AN - SCOPUS:77950351528

VL - 24

SP - 341

EP - 346

JO - Perfusion

JF - Perfusion

SN - 0267-6591

IS - 5

ER -